Search results
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
Zacks via Yahoo News· 2 weeks agoThe FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat...
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
Zacks via Yahoo News· 2 weeks agoIonis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading...
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
Zacks via Yahoo News· 1 month agoIt was a busy week for the biotech sector, with numerous data presentations by biotech companies at...
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo News· 1 month agoIt has been about a month since the last earnings report for Ionis Pharmaceuticals (IONS). Shares...
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
Zacks via Yahoo News· 1 month agoViking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its...
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Zacks via Yahoo News· 1 month agoBiogen BIIB announced that the European Commission (EC) has granted marketing approval to Qalsody...
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar...
Zacks via Yahoo News· 1 month agoFor Immediate Release Chicago, IL – May 24, 2024 – Zacks.com announces the list of stocks featured...
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
Zacks via Yahoo News· 2 months agoIonis Pharmaceuticals IONS reported a loss of 98 cents per share for first-quarter 2024, which was...
Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks via Yahoo News· 2 months agoThe headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in...
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
Zacks via Yahoo News· 2 months agoIonis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 10.91% and 9.51%,...